Spero Therapeutics Inc (SPRO) Institutional Ownership Tracker (Q2 2026)

SPRO ranks #5603 out of 37696 tracked stocks by institutional interest, inside the more closely watched half of our coverage.

SPRO is a disclosed holding of Jim Simons (Renaissance Technologies), one of the tracked superinvestors on AlphaSMO — it makes up 0.0% of that fund's own 13F portfolio.

63 institutions disclose a position in SPRO, but none treat it as a major bet — even GSK plc, its most concentrated holder, allocates just 3.4% of its own portfolio to it.

FNY Investment Advisers, LLC has added to its SPRO position for two straight quarters, increasing it by $13.0K to reach $25.0K today.

Assenagon Asset Management S.A. has trimmed its SPRO position for two straight quarters, cutting it by $22.1K while still holding $21.5K.

SPRO is down 2.7% today, but institutions show net buying of $3.9M this quarter — a divergence between today's price move and the underlying institutional flow.

SPRO posted net income of $7.4M over the trailing twelve months, and currently trades at a P/E of 8.8.

• Profitable — net income of $7.4M over the trailing twelve months
• Revenue grew 9647.3% year over year
• Net income improved year over year, from -$53.6M to $7.4M
• Operating cash flow was negative, using $12.6M in cash
• Current ratio of 7.59x — enough short-term assets to cover short-term liabilities
• Liabilities run 0.17x equity — within a conventional range